A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors

NCT01176500 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Colon Cancer
Lung Cancer
Cervical Cancer
Renal Cell Carcinoma
Uterine Cancer

Interventions

DRUG: (18)Fluciclatide

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]